Annovis Bio (ANVS) Competitors

Annovis Bio logo
$0.76 -0.17 (-17.83%)
Closing price 03:59 PM Eastern
Extended Trading
$0.78 +0.02 (+3.15%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ANVS vs. ALXO, ADAG, PRQR, ABEO, and RNA

Should you buy Annovis Bio stock or one of its competitors? Annovis Bio's main competitors and comparable companies include ALX Oncology (ALXO), Adagene (ADAG), ProQR Therapeutics (PRQR), Abeona Therapeutics (ABEO), and Avidity Biosciences (RNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Annovis Bio compare to ALX Oncology?

Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

ALX Oncology's return on equity of -90.30% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -986.96% -261.39%
ALX Oncology N/A -90.30%-67.28%

Annovis Bio currently has a consensus target price of $12.00, indicating a potential upside of 1,197.30%. ALX Oncology has a consensus target price of $4.75, indicating a potential upside of 356.73%. Given Annovis Bio's higher probable upside, equities research analysts plainly believe Annovis Bio is more favorable than ALX Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
ALX Oncology
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 15.9% of Annovis Bio shares are owned by company insiders. Comparatively, 12.4% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.64N/A
ALX OncologyN/AN/A-$101.69M-$1.13N/A

Annovis Bio has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

In the previous week, Annovis Bio had 5 more articles in the media than ALX Oncology. MarketBeat recorded 7 mentions for Annovis Bio and 2 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.74 beat Annovis Bio's score of 0.44 indicating that ALX Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annovis Bio
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ALX Oncology
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ALX Oncology beats Annovis Bio on 7 of the 13 factors compared between the two stocks.

How does Annovis Bio compare to Adagene?

Annovis Bio (NYSE:ANVS) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Adagene has higher revenue and earnings than Annovis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.64N/A
Adagene$9.29M11.38-$17.61MN/AN/A

In the previous week, Annovis Bio had 5 more articles in the media than Adagene. MarketBeat recorded 6 mentions for Annovis Bio and 1 mentions for Adagene. Adagene's average media sentiment score of 1.00 beat Annovis Bio's score of 0.44 indicating that Adagene is being referred to more favorably in the news media.

Company Overall Sentiment
Annovis Bio Neutral
Adagene Positive

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 15.9% of Annovis Bio shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Annovis Bio currently has a consensus target price of $10.00, indicating a potential upside of 1,214.06%. Adagene has a consensus target price of $8.25, indicating a potential upside of 415.63%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Adagene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Adagene
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Annovis Bio has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, Adagene has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Adagene's return on equity of 0.00% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -986.96% -261.39%
Adagene N/A N/A N/A

Summary

Adagene beats Annovis Bio on 8 of the 12 factors compared between the two stocks.

How does Annovis Bio compare to ProQR Therapeutics?

Annovis Bio (NYSE:ANVS) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Annovis Bio has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.64N/A
ProQR Therapeutics$18.36M6.77-$47.73M-$0.46N/A

Annovis Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -205.69%. ProQR Therapeutics' return on equity of -72.78% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -986.96% -261.39%
ProQR Therapeutics -205.69%-72.78%-36.78%

Annovis Bio has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 15.9% of Annovis Bio shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Annovis Bio presently has a consensus price target of $10.00, suggesting a potential upside of 1,214.06%. ProQR Therapeutics has a consensus price target of $7.60, suggesting a potential upside of 544.07%. Given Annovis Bio's higher possible upside, equities analysts plainly believe Annovis Bio is more favorable than ProQR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
ProQR Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

In the previous week, ProQR Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 7 mentions for ProQR Therapeutics and 6 mentions for Annovis Bio. ProQR Therapeutics' average media sentiment score of 0.83 beat Annovis Bio's score of 0.44 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annovis Bio
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ProQR Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ProQR Therapeutics beats Annovis Bio on 10 of the 16 factors compared between the two stocks.

How does Annovis Bio compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Annovis Bio has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -160.30%. Abeona Therapeutics' return on equity of -44.82% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Abeona Therapeutics-160.30% -44.82% -32.51%
Annovis Bio N/A -986.96%-261.39%

Abeona Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 707.69%. Annovis Bio has a consensus price target of $10.00, indicating a potential upside of 1,214.06%. Given Annovis Bio's higher possible upside, analysts clearly believe Annovis Bio is more favorable than Abeona Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Abeona Therapeutics had 11 more articles in the media than Annovis Bio. MarketBeat recorded 17 mentions for Abeona Therapeutics and 6 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.44 beat Abeona Therapeutics' score of 0.35 indicating that Annovis Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Annovis Bio
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 15.9% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abeona Therapeutics has higher revenue and earnings than Annovis Bio. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abeona Therapeutics$5.82M25.53$71.18M-$1.07N/A
Annovis BioN/AN/A-$28.85M-$1.64N/A

Abeona Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Summary

Abeona Therapeutics beats Annovis Bio on 10 of the 15 factors compared between the two stocks.

How does Annovis Bio compare to Avidity Biosciences?

Annovis Bio (NYSE:ANVS) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

15.8% of Annovis Bio shares are held by institutional investors. 15.9% of Annovis Bio shares are held by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Avidity Biosciences' return on equity of 0.00% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -986.96% -261.39%
Avidity Biosciences N/A N/A N/A

Annovis Bio has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$28.85M-$1.64N/A
Avidity Biosciences$35.84M3.07-$36.78M-$2.15N/A

Annovis Bio currently has a consensus price target of $10.00, suggesting a potential upside of 1,214.06%. Avidity Biosciences has a consensus price target of $33.00, suggesting a potential upside of 413.22%. Given Annovis Bio's higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than Avidity Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Avidity Biosciences
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.63

In the previous week, Annovis Bio had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 6 mentions for Annovis Bio and 5 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.96 beat Annovis Bio's score of 0.44 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annovis Bio
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avidity Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Annovis Bio and Avidity Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANVS vs. The Competition

MetricAnnovis BioBiotechnology IndustryHealthcare SectorNYSE Exchange
Market Cap$36.45M$4.15B$7.85B$23.49B
Dividend YieldN/A3.62%2.46%3.79%
P/E Ratio-0.4626.5532.9124.79
Price / SalesN/A16.028.593.24
Price / CashN/A26.3721.9315.51
Price / Book1.194.074.403.66
Net Income-$28.85M-$22.86M$3.52B$1.08B
7 Day Performance-15.26%-7.26%-5.34%-3.09%
1 Month Performance-24.35%-4.96%-3.61%-1.21%
1 Year Performance-67.96%-2.87%0.01%5.63%

Annovis Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANVS
Annovis Bio
3.6753 of 5 stars
$0.76
-17.8%
$10.00
+1,214.1%
-61.1%$36.45MN/AN/A7
ALXO
ALX Oncology
2.2562 of 5 stars
$1.17
-8.7%
$4.60
+292.2%
-24.6%$162.48MN/AN/A48
ADAG
Adagene
3.3773 of 5 stars
$2.15
+1.4%
$8.25
+283.9%
-6.6%$141.94M$7.67MN/A128
PRQR
ProQR Therapeutics
3.6266 of 5 stars
$1.35
-2.5%
$7.60
+465.1%
-35.0%$141.71M$17.99MN/A166
ABEO
Abeona Therapeutics
3.2385 of 5 stars
$2.48
-2.6%
$21.00
+748.5%
-45.6%$141.52M$5.82MN/A226

Related Companies and Tools


This page (NYSE:ANVS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners